Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (29)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pectasides, D.
Right arrow Articles by Skarlos, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pectasides, D.
Right arrow Articles by Skarlos, D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 15:493-497, 2004
© 2004 European Society for Medical Oncology

Original Paper

Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study

Received 10 July 2003; revised 3 November 2003; accepted 19 December 2003

Background:

To investigate the efficacy and toxicity of the combination of gemcitabine and oxaliplatin (GEMOX) in patients with relapsed or cisplatin-refractory non-seminomatous germ cell tumors (NSGCT).

Patients and methods:

Twenty-nine patients with relapsed or cisplatin-refractory NSGCT were treated with gemcitabine 1000 mg/m2 on days 1 and 8 followed by oxaliplatin 130 mg/m2 on day 1 every 3 weeks for a maximum of six cycles. Twenty-four patients (83%) were considered refractory and five (17%) absolutely refractory to cisplatin.

Results:

Twenty-eight patients were assessable for response. Overall, nine patients (32%) achieved a favourable response (complete response, four; partial response, five). One of the complete responders relapsed after 7 months and went into disease-free status lasting for 11+ months after resection of lung metastases. The rest of the complete responders are continuously disease-free at 14+, 19+ and 28+ months with the study regimen plus or minus surgery. One of the complete responders had absolutely cisplatin-refractory disease and another one presented with a late relapse. Toxicity was primarily hematological and generally manageable: 62% of patients experienced grade 3/4 neutropenia, 10% neutropenic fever and 41% grade 3/4 thrombocytopenia. Non-hematological toxicity consisted mainly of nausea/vomiting. Three patients (10%) developed grade 3 neurotoxicity and discontinued treatment.

Conclusions:

The combination of GEMOX is an active, moderately toxic and easily administered regimen in patients with relapsed or cisplatin-refractory NSGCT. The 14% long-term disease-free status accomplished in this heavily pretreated patient population is quite encouraging.

D. Pectasides1,*, M. Pectasides1, D. Farmakis1, G. Aravantinos2, M. Nikolaou1, M. Koumpou1, A. Gaglia1, V. Kostopoulou1, N. Mylonakis1 and D. Skarlos3

1 Second Department of Medical Oncology, Metaxas Memorial Cancer Hospital, Piraeus; 2 Third Department of Medical Oncology, ‘Ag. Anargiri’ Cancer Hospital, Athens; 3 Second Department of Medical Oncology, ‘Eric Dynan’ Hospital, Athens, Greece

Key words: cisplatin-refractory disease, gemcitabine, germ cell tumors, oxaliplatin, salvage therapy, testicular cancer


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Anticancer ResHome page
D. PECTASIDES, G. PAPAXOINIS, M. NIKOLAOU, C. VALAVANIS, G. ARAVANTINOS, G. FOUNTZILAS, N. TAMVAKIS, E. PECTASIDES, I. LEKKA, P. ARAPANTONI-DADIOTI, et al.
Analysis of 7 Immunohistochemical Markers in Male Germ Cell Tumors Demonstrates the Prognostic Significance of p53 and MIB-1
Anticancer Res, February 1, 2009; 29(2): 737 - 744.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
C. Bokemeyer, K. Oechsle, F. Honecker, F. Mayer, J. T. Hartmann, C. F. Waller, I. Bohlke, and C. Kollmannsberger
Combination chemotherapy with gemcitabine, oxaliplatin, and paclitaxel in patients with cisplatin-refractory or multiply relapsed germ-cell tumors: a study of the German Testicular Cancer Study Group
Ann. Onc., March 1, 2008; 19(3): 448 - 453.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. R. Feldman, G. J. Bosl, J. Sheinfeld, and R. J. Motzer
Medical Treatment of Advanced Testicular Cancer
JAMA, February 13, 2008; 299(6): 672 - 684.
[Abstract] [Full Text] [PDF]

Home page
 Postgrad. Med. J.Home page
O. Khan and A. Protheroe
Testis cancer
Postgrad. Med. J., October 1, 2007; 83(984): 624 - 632.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J Shamash, T Powles, K Mutsvangwa, P Wilson, W Ansell, E Walsh, D Berney, J Stebbing, and T Oliver
A phase II study using a topoisomerase I-based approach in patients with multiply relapsed germ-cell tumours
Ann. Onc., May 1, 2007; 18(5): 925 - 930.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. H. Einhorn, M. J. Brames, B. Juliar, and S. D. Williams
Phase II Study of Paclitaxel Plus Gemcitabine Salvage Chemotherapy for Germ Cell Tumors After Progression Following High-Dose Chemotherapy With Tandem Transplant
J. Clin. Oncol., February 10, 2007; 25(5): 513 - 516.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
G. Sonpavde, T. E. Hutson, and B. J. Roth
Management of Recurrent Testicular Germ Cell Tumors
Oncologist, January 1, 2007; 12(1): 51 - 61.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
G. Di Lorenzo, R. Autorino, A. Giordano, M. Giuliano, M. D'Armiento, A. R. Bianco, and S. De Placido
FOLFOX-4 in Pre-treated Patients with Advanced Transitional Cell Carcinoma of the Bladder
Jpn. J. Clin. Oncol., December 1, 2004; 34(12): 747 - 750.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.